Ken Griffin Trans Medics Group, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$135.68 - $176.11 $5.37 Million - $6.97 Million	39,600 Added 25.71%	193,600 $30.4 Million
Q2 2024 Aug 14, 2024	BUY	$72.62 - $150.62 $8.06 Million - $16.7 Million	111,000 Added 258.14%	154,000 $23.2 Million
Q1 2024 May 15, 2024	BUY	$70.86 - $89.93 $850,320 - $1.08 Million	12,000 Added 38.71%	43,000 $3.18 Million
Q4 2023 Feb 14, 2024	SELL	$36.74 - $81.08 $609,884 - $1.35 Million	-16,600 Reduced 34.87%	31,000 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$53.47 - $96.07 $1.36 Million - $2.45 Million	25,500 Added 115.38%	47,600 $2.61 Million
Q2 2023 Aug 14, 2023	SELL	$66.23 - $88.73 $119,214 - $159,714	-1,800 Reduced 7.53%	22,100 $1.86 Million
Q1 2023 May 15, 2023	SELL	$53.63 - $82.33 $246,698 - $378,718	-4,600 Reduced 16.14%	23,900 $1.81 Million
Q4 2022 Feb 14, 2023	SELL	$39.08 - $64.29 $328,272 - $540,036	-8,400 Reduced 22.76%	28,500 $1.76 Million
Q3 2022 Nov 14, 2022	BUY	$31.56 - $55.75 $650,136 - $1.15 Million	20,600 Added 126.38%	36,900 $1.54 Million

397

31.7M

466K

286K

Ticker TMDX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 31,831,400
Market Cap $2.03B
Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and custo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.